A Phase II Study to Assess the Safety and Efficacy of the Dual mTORC1/2 and PI3K Inhibitor Bimiralisib (PQR309) in Relapsed, Refractory Lymphoma

Bimiralisib is an orally bioavailable pan-phosphatidylinositol 3-kinase and mammalian target of rapamycin inhibitor which has shown activity against lymphoma in preclinical models. This phase I/II study evaluated the response rate to bimiralisib at 2 continuous dose levels (60 mg and 80 mg) in patie...

Descripción completa

Detalles Bibliográficos
Autores principales: Collins, Graham P., Eyre, Toby A., Schmitz-Rohmer, Debora, Townsend, William, Popat, Rakesh, Giulino-Roth, Lisa, Fields, Paul A., Krasniqi, Fatime, Soussain, Carole, Stathis, Anastasios, Andjelkovic, Nebojsa, Cunningham, David, Mandic, Danijela, Radulovic, Sinisa, Tijanic, Ivan, Horowitz, Netanel A., Kurtovic, Sabira, Schorb, Elisabeth, Schmidt, Christian, Dimitrijević, Saša, Dreyling, Martin
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Lippincott Williams & Wilkins 2021
Materias:
Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660000/
https://www.ncbi.nlm.nih.gov/pubmed/34901759
http://dx.doi.org/10.1097/HS9.0000000000000656

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8660000/
https://www.ncbi.nlm.nih.gov/pubmed/34901759
http://dx.doi.org/10.1097/HS9.0000000000000656

Ejemplares similares